Are there any regulatory or legal risks remaining that could threaten future compliance?

Regulatory outlook:

Polyrizon’s announcement that it has “regained compliance with all applicable Nasdaq listing requirements” removes the immediate listing‑delisting risk that had been a drag on the stock. The company now satisfies the Nasdaq panel’s core criteria—minimum market‑cap, shareholder‑equity, and timely SEC reporting—so the most acute compliance threat is gone. However, Nasdaq compliance is an ongoing condition; any future lapse in quarterly filing deadlines, a drop below the market‑cap threshold, or a failure to meet corporate‑governance standards could reignite the risk. From a legal‑regulatory standpoint, those are the only remaining Nasdaq‑related headwinds.

Broader biotech‑sector risks:

Beyond the exchange rules, Polyrizon remains exposed to the sector’s typical regulatory hurdles, chiefly FDA and other health‑authority approvals for its intranasal products. Delays, adverse trial data, or a failure to secure clearances could materially affect cash‑flow expectations and, indirectly, its ability to meet Nasdaq’s financial metrics. While the Nasdaq panel’s decision is a positive catalyst, investors should still monitor the company’s pipeline milestones, upcoming 10‑K/10‑Q filings, and any pending litigation or intellectual‑property disputes that could surface.

Trading implication:

With the immediate Nasdaq compliance issue resolved, the stock can now trade on fundamentals and technicals rather than a “compliance‑risk” discount. If the company continues to meet filing deadlines and demonstrates steady progress on its product pipeline, the upside potential is intact. Traders may consider a neutral‑to‑bullish stance, but keep a tight stop just below the next filing deadline or any known regulatory milestone (e.g., FDA submission dates). Continuous monitoring of SEC filing dates and FDA trial updates will be essential to gauge whether any residual regulatory or legal risk re‑emerges.